Enliven Therapeutics’ reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.
The lead drug candidate of Imara failed two separate mid-stage clinical trials evaluating it in rare, inherited hemoglobin disorders. Imara had been planning to advance the small molecule to yet another Phase 2 study in heart failure, but in light of the twin trial failures, the biotech is now weighing “strategic options.”
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
The company is developing a drug that targets the same pathway as the chemotherapy agent hydroxyurea, but is designed for a better safety profile.